Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging

Fink, James R.; Muzi, Mark; Peck, Melinda; Krohn, Kenneth A.

doi:10.2967/jnumed.113.131516

Cited by 181 publications

(98 citation statements)

References 100 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the last two decades there has been an increase in the use of magnetic particles and magnetic microspheres including iron oxide nanoparticles (IONPs) and superparamagnetic iron oxide nanoparticles (SPIONs) for bio-medical applications such as imaging, diagnostics, therapies and theranostics, but their suitability for these applications ultimately depends on their biodistribution and toxicity profiles [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]. The two main administration routes for IONPs into the body are intravenous (IV) injection and intraperitoneal (IP) injection.…”

Section: Introductionmentioning

confidence: 99%

Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration

Pham

Colvin

Phạm

et al. 2018

IJMS

View full text Add to dashboard Cite

Nanomedicine is an emerging field with great potential in disease theranostics. We generated sterically stabilized superparamagnetic iron oxide nanoparticles (s-SPIONs) with average core diameters of 10 and 25 nm and determined the in vivo biodistribution and clearance profiles. Healthy nude mice underwent an intraperitoneal injection of these s-SPIONs at a dose of 90 mg Fe/kg body weight. Tissue iron biodistribution was monitored by atomic absorption spectroscopy and Prussian blue staining. Histopathological examination was performed to assess tissue toxicity. The 10 nm s-SPIONs resulted in higher tissue-iron levels, whereas the 25 nm s-SPIONs peaked earlier and cleared faster. Increased iron levels were detected in all organs and body fluids tested except for the brain, with notable increases in the liver, spleen, and the omentum. The tissue-iron returned to control or near control levels within 7 days post-injection, except in the omentum, which had the largest and most variable accumulation of s-SPIONs. No obvious tissue changes were noted although an influx of macrophages was observed in several tissues suggesting their involvement in s-SPION sequestration and clearance. These results demonstrate that the s-SPIONs do not degrade or aggregate in vivo and intraperitoneal administration is well tolerated, with a broad and transient biodistribution. In an ovarian tumor model, s-SPIONs were shown to accumulate in the tumors, highlighting their potential use as a chemotherapy delivery agent.

show abstract

Section: Introductionmentioning

confidence: 99%

Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration

Pham

Colvin

Phạm

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…The combination of MR-based anatomic and physiologic imaging with temporally and spatially matched PET-based molecular imaging allows us to answer questions pertaining to prognosis, plan therapeutic approaches, and assess response to treatment with greater confidence than is possible with either modality alone (Box 3). 21 …”

Section: Applicationsmentioning

confidence: 99%

“…21,67 PET/MR has emerged as an important tool in neuro-oncologic research providing spatially and temporally matched molecular, physiologic, and anatomic data for the study of tumor biology and therapies as well as a means for cross-validating advanced MR techniques with PET-derived data. Studies are emerging showing that multiparametric tumor maps incorporating PWI, DWI, and MRS with molecular PET data predict tumor grade, define tumor extent, and correlate with response to therapy.…”

Section: Applicationsmentioning

confidence: 99%

Neurologic Applications of PET/MR Imaging

Miller‐Thomas

Benzinger

2017

Magnetic Resonance Imaging Clinics of North America

View full text Add to dashboard Cite

Synopsis PET/MR benefits neurological clinical care and research by providing spatially and temporally matched anatomic MR imaging, advanced MR physiologic imaging, and metabolic PET imaging. MR imaging sequences and PET tracers can be modified to target physiology specific to a neurological disease process, with applications in neuro-oncology, epilepsy, dementia, cerebrovascular disease, and psychiatric and neurological research. Simultaneous PET/MR provides efficient acquisition of multiple temporally matched datasets, and opportunities for motion correction and improved anatomic assignment of PET data. Current challenges include optimizing MR based attenuation correction and necessity for dual expertise in PET and MR.

show abstract

“…PET and MR images can be co-registered to locate the area of abnormality more accurately. The most commonly used tracer for brain PET imaging is 18 F-2-fluoro-2-deoxy-D-glucose (FDG), which gives information about glucose metabolism in tumours when compared with the contralateral normal grey/white matter 26. Another commonly used tracer, 11 C-methionine (MET), is an amino acid analogue, meaning it has higher differential uptake in tumours than the surrounding brain tissue 26.…”

Section: Introductionmentioning

confidence: 99%

“…The most commonly used tracer for brain PET imaging is 18 F-2-fluoro-2-deoxy-D-glucose (FDG), which gives information about glucose metabolism in tumours when compared with the contralateral normal grey/white matter 26. Another commonly used tracer, 11 C-methionine (MET), is an amino acid analogue, meaning it has higher differential uptake in tumours than the surrounding brain tissue 26. When planning surgical resection margins in gliomas, PET imaging using both FDG and MET can give metabolic information that is additional to that from conventional MR imaging: Pirotte et al 27 showed that FDG and MET PET imaging gave tumour resection contours that differed from MRI alone in 80% of the 66 patients.…”

Section: Introductionmentioning

confidence: 99%

Imaging in low-grade glioma: a guide for neurologists

2017

View full text Add to dashboard Cite

The management of low-grade glioma (LGG) is shifting as evidence has emergedthat refutes the previously commonplace imaging-based 'watch and wait' approach, in favour of early aggressive surgical resection. This coupled with the recent 2016 update to the World Health Organisation Classification of Tumours of the Central Nervous System is changing LGG imaging and management. Recently in the contemporary management of low-grade glioma and the changes to this grading system were discussed in detail. In this complementary article, we discuss the role of imaging in the diagnosis, surgical planning and post-treatment follow-up of LGG. We describe the principles of imaging these tumours and use several cases to highlight some difficult scenarios.

show abstract

Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging

Cited by 181 publications

References 100 publications

Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration

Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration

Neurologic Applications of PET/MR Imaging

Imaging in low-grade glioma: a guide for neurologists

Contact Info

Product

Resources

About